Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EED | O75530 | 3/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30062498 | 1.00 | EED (0.32) | EED | |
| SCHEMBL28616526 | 0.81 | EED (0.39) | EED | |
| SCHEMBL28642389 | 0.79 | EED (0.34) | EED | |
| SCHEMBL22362980 | 0.79 | ABL1 (0.35) | EED | |
| SCHEMBL23748191 | 0.78 | EED (0.35) | EED | |
| SCHEMBL22362856 | 0.78 | EED (0.36) | EED | |
| SCHEMBL5417502 | 0.78 | EED (0.36) | EED | |
| SCHEMBL31038076 | 0.78 | EED (0.36) | EED | |
| SCHEMBL17097240 | 0.74 | EED (0.37) | EED | |
| SCHEMBL28736022 | 0.73 | IDO1 (0.48) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220401422-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-alpha AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2022-12-22 | — | — | US | disclosed |
| CN-115485275-A | Compounds and compositions that inhibit HIF 2-alpha activity and methods of use thereof | 诺华股份有限公司 | 2022-12-16 | — | — | CN | disclosed |
| WO-2021217508-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2α AND THEIR METHODS OF USE | NOVARTIS AG (CH) | 2021-11-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220401422-A1 | COMPOUNDS AND COMPOSITIONS FOR INHIBITING THE ACTIVITY OF HIF2-alpha AND THEIR METHODS OF USE | HIF1AN, HIF1A, EGLN2 | EED 1118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.